RNA Mapping of Mutant Myotonic Dystrophy Protein Kinase 3'-Untranslated Region Transcripts.
- Author:
Min Sun SONG
1
;
Seong Wook LEE
Author Information
1. Department of Molecular Biology, BK21 Graduate Program for RNA Biology, Institute of Nanosensor and Biotechnology, Dankook University, Yongin 448-701, Korea. SWL0208@dankook.ac.kr
- Publication Type:Original Article
- Keywords:
group I intron;
myotonic dystrophy protein kinase;
RNA mapping;
RNA replacement;
trans-splicing ribozyme;
trinucleotide repeat expansion
- MeSH:
Cytoplasm;
Myotonic Dystrophy;
Neurodegenerative Diseases;
Protein Kinases;
Protein-Serine-Threonine Kinases;
Retention (Psychology);
RNA;
RNA, Catalytic;
Trinucleotide Repeat Expansion
- From:Genomics & Informatics
2009;7(4):181-186
- CountryRepublic of Korea
- Language:English
-
Abstract:
Myotonic dystrophy type 1 (DM1), which is a dominantly inherited neurodegenerative disorder, results from a CTG trinucleotide repeat expansion in the 3'-untranslated region (3'-UTR) of the myotonic dystrophy protein kinase (DMPK) gene. Retention of mutant DMPK (mDMPK) transcripts in the nuclei of affected cells has been known to be the main cause of pathogenesis of the disease. Thus, reducing the RNA toxicity through elimination of the mutant RNA has been suggested as one therapeutic strategy against DM1. In this study, we suggested RNA replacement with a trans -splicing ribozyme as an alternate genetic therapeutic approach for amelioration of DM1. To this end, we identified the regions of mDMPK 3'-UTR RNA that were accessible to ribozymes by using an RNA mapping strategy based on a trans - splicing ribozyme library. We found that particularly accessible sites were present not only upstream but also downstream of the expanded repeat sequence. Repair or replacement of the mDMPK transcript with the specific ribozyme will be useful for DM1 treatment through reduction of toxic mutant transcripts and simultaneously restore wild-type DMPK or release nucleus-entrapped mDMPK transcripts to the cytoplasm.
